Last 3 months treatment in patients with versus without continuously ID at the 12-month follow-up
| Patients on systemic glucocorticoids | Patients on | |||||||
|---|---|---|---|---|---|---|---|---|
| Low dose | High dose | csDMARDs | bDMARDs | |||||
| Not continuously ID for at least 3 months n (%) | Continuously ID for at least 3 months n (%) | Not continuously ID for at least 3 months n (%) | Continuously ID for at least 3 months n (%) | Not continuously ID for at least 3 months n (%) | Continuously ID for at least 3 months n (%) | Not continuously ID for at least 3 months n (%) | Continuously ID for at least 3 months n (%) | |
| All patients with JIA | 43 (10.3) | 14 (5.1) | 31 (7.4) | 3 (1.9) | 282 (67.3) | 166 (60.1) | 106 (25.3) | 34 (12.3) |
| Persistent oligoarthritis | 6 (4.0) | 0 (0.0) | 4 (2.7) | 1 (1.0) | 67 (44.4) | 31 (31.0) | 10 (6.6) | 1 (1.0) |
| Extended oligoarthritis | 5 (13.5) | 2 (8.0) | 4 (10.8) | 0 (0.0) | 31 (83.8) | 21 (84.0) | 10 (27.0) | 2 (8.0) |
| Polyarthritis RF negative | 16 (13.9) | 8 (10.0) | 13 (11.3) | 1 (1.3) | 100 (87.0) | 72 (90.0) | 42 (36.5) | 12 (15.0) |
| Polyarthritis RF positive | 3 (60.0) | 1 (20.0) | 1 (20.0) | 0 (0.0) | 4 (80.0) | 4 (80.0) | 3 (60.0) | 1 (20.0) |
| Psoriatic arthritis | 3 (12.0) | 0 (0.0) | 3 (12.0) | 0 (0.0) | 20 (80.0) | 8 (88.9) | 11 (44.0) | 0 (0.0) |
| Enthesitis-related arthritis | 5 (9.4) | 0 (0.0) | 3 (5.7) | 0 (0.0) | 36 (67.9) | 14 (66.7) | 13 (24.5) | 4 (19.1) |
| Systemic arthritis | 4 (44.4) | 3 (18.8) | 1 (11.1) | 1 (6.3) | 7 (77.8) | 8 (50.0) | 7 (77.8) | 10 (62.5) |
| Undifferentiated arthritis | 1 (4.2) | 0 (0.0) | 2 (8.3) | 0 (0.0) | 17 (70.8) | 8 (40.0) | 10 (41.7) | 4 (20.0) |
bDMARD, biologic disease-modifying antirheumatic drug; csDMARDs, conventional synthetic DMARD; ID, inactive disease; JIA, juvenile idiopathic arthritis; RF, rheumatoid factor.